Overview

Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function

Status:
Not yet recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of Besifovir and its metabolite, LB80331, in participants with normal and impaired renal function
Phase:
Phase 1
Details
Lead Sponsor:
IlDong Pharmaceutical Co Ltd
Treatments:
Maleic acid